Shots:
- Biocon and Clinton Health Access Initiative collaborate to expand the offering of oncology biosimilars in over 30 countries including Africa and Asia as a part of the Cancer Access Partnership (CAP)
- The collaboration strengthens Biocon’s mission to address unmet needs of patients in Asia and Africa for advanced cancer therapies via cost effective biosimilars. The collaboration follows the initiation of our Mission 10 cents to provide insulins for people with diabetes in LMICs
- Biocon will initially supply bTrastuzumab and bPegfilgrastim and will expand the arrangement to include other biosimilars
Click here to read full press release/ article | Ref: Biocon | Image: Logo.wine
The post Biocon Biologics Signs an Agreement with CHAI to Expand Access to its Oncology Biosimilars in 30 Countries first appeared on PharmaShots.
